Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii

Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic

This study assesses the effect of quadruple therapy for H. pylori, with the addition of probiotics Saccharomyces boulardii. In addition, he assesses whether this combination reduces the frequency of adverse effects of eradication therapy, and whether it affects the compliance.

Study Overview

• Status: Unknown
• Conditions: Helicobacter Pylori Infection
• Intervention / Treatment: Drug: Saccharomyces boulardii; Drug: Placebo

Detailed Description

Standard triple therapy for H. pylori infection proved to be insufficiently effective, primarily due to antibiotics resistance.Therefore, the latest Maastricht consensus suggests using bismuth-quadruple or non-bismuth-quadruple therapy, in regions with high clarithromycin resistance. The addition of probiotics with eradication therapy has never become a standard treatment. However, the Maastricht consensus suggest that the addition of probiotics could increase the effectiveness of quadruple therapy.

The study was designed as a prospective, double-blind, randomized, case-control intervention study.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Miodrag Krstic, MD, PhD; Phone Number: +381113615575; Email: krstic.miodrag61@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Dyspepsia
• Patients not treated for H. Pylori
• Age of 18-50 years
• Positive urea breath test

Exclusion Criteria:

• Alarm symptoms (anemia, persistent vomiting, hematemesis, dysphagia, significant weight loss, palpable mass in abdomen)
• Gastric cancer
• Immunosuppressive therapy
• Use of acetylsalicylic acid
• Severe renal failure
• Severe liver failure
• Immunodeficiency
• Proven malignant disease
• Penicillin allergy
• Allergy to any component of dietary supplement (Saccharomyces boulardii and Vitamin D)
• Chronic alcoholism
• Pregnancy
• Lactation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: S.boulardi; Quadruple eradication therapy with S. boulardi	Drug: Saccharomyces boulardii; Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week; Other Names: Rabeprazole; Amoxicillin; Clarithromycin; Metronidazole
Placebo Comparator: Placebo; Quadruple eradication therapy without S. boulardi	Drug: Placebo; Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week; Other Names: Rabeprazole; Amoxicillin; Clarithromycin; Metronidazole

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Result of urea breath test (Eradication of H.pylori)	Test remains positive (Eradication of H.pylori unsuccessful) or test becomes negative (eradication of H.pylori successful)	baseline to 8 weeks after the introduction of the therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Side effects of eradication therapy	Number and severity of adverse events of standard eradication therapy	baseline to 8 weeks after the introduction of the therapy
Compliance of eradication therapy	Patient successfully completed prescribed therapy	baseline to 8 weeks after the introduction of the therapy

Collaborators and Investigators

• Sponsor: Clinical Centre of Serbia

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2019
• Primary Completion (Anticipated): June 1, 2020
• Study Completion (Anticipated): June 1, 2020

Study Registration Dates

• First Submitted: June 12, 2019
• First Submitted That Met QC Criteria: June 21, 2019
• First Posted (Actual): June 25, 2019

Study Record Updates

• Last Update Posted (Actual): June 25, 2019
• Last Update Submitted That Met QC Criteria: June 21, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: Helicobacter Pylori; Saccharomyces boulardi; Eradication therapy
• Additional Relevant MeSH Terms: Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Helicobacter Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Gastrointestinal Agents; Anti-Bacterial Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Protein Synthesis Inhibitors; Antiprotozoal Agents; Antiparasitic Agents; Anti-Ulcer Agents; Proton Pump Inhibitors; Metronidazole; Rabeprazole; Amoxicillin; Clarithromycin
• Other Study ID Numbers: AB-2019-4

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No